06/02/2026 Biologics as add-on therapy for severe asthma
The Ministry of Health’s Drug Advisory Committee has recommended:
- Benralizumab 30 mg/1 mL autoinjector pen for treating severe eosinophilic asthma; and
- Omalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes for treating severe allergic asthma.
Funding status
RBenralizumab 30 mg/ml autoinjector pen is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
RBenralizumab should be used in line with the additional clinical criteria for initiation and renewal listed in the Annex.
ROmalizumab biosimilar (Omlyclo) 75 mg/0.5 mL and 150 mg/1 mL pre-filled syringes are recommended for inclusion on the Standard Drug List (SDL) from 1 April 2026.
NRSDL subsidy and MAF assistance do not apply to any formulations or strengths of dupilumab, mepolizumab, omalizumab reference biologic (Xolair) or tezepelumab for treating severe asthma.